
### [NCIT:C68611](http://purl.obolibrary.org/obo/NCIT_C68611)
**Label:** Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

**Subclasses:** [NCIT:C115072](http://purl.obolibrary.org/obo/NCIT_C115072) (Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7), [NCIT:C115071](http://purl.obolibrary.org/obo/NCIT_C115071) (Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7), [NCIT:C8193](http://purl.obolibrary.org/obo/NCIT_C8193) (Paranasal Sinus Squamous Cell Carcinoma), [NCIT:C115070](http://purl.obolibrary.org/obo/NCIT_C115070) (Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7), [NCIT:C8192](http://purl.obolibrary.org/obo/NCIT_C8192) (Nasal Cavity Squamous Cell Carcinoma), [NCIT:C54284](http://purl.obolibrary.org/obo/NCIT_C54284) (Keratinizing Paranasal Sinus Squamous Cell Carcinoma), [NCIT:C115443](http://purl.obolibrary.org/obo/NCIT_C115443) (Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma), [NCIT:C54285](http://purl.obolibrary.org/obo/NCIT_C54285) (Keratinizing Nasal Cavity Squamous Cell Carcinoma), [NCIT:C6066](http://purl.obolibrary.org/obo/NCIT_C6066) (Sphenoid Sinus Squamous Cell Carcinoma), [NCIT:C115073](http://purl.obolibrary.org/obo/NCIT_C115073) (Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7), 

**Class expressions from DL-Learner:**

- Thing 53.20%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40128](http://purl.obolibrary.org/obo/NCIT_C40128) (Fallopian Tube Leiomyosarcoma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40127](http://purl.obolibrary.org/obo/NCIT_C40127) (Fallopian Tube Leiomyoma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40125](http://purl.obolibrary.org/obo/NCIT_C40125) (Fallopian Tube Adenosarcoma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40124](http://purl.obolibrary.org/obo/NCIT_C40124) (Fallopian Tube Carcinosarcoma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40122](http://purl.obolibrary.org/obo/NCIT_C40122) (Pelvic Pain))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40116](http://purl.obolibrary.org/obo/NCIT_C40116) (Fallopian Tube Metaplastic Papillary Tumor))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40114](http://purl.obolibrary.org/obo/NCIT_C40114) (Fallopian Tube Serous Cystadenofibroma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40112](http://purl.obolibrary.org/obo/NCIT_C40112) (Fallopian Tube Papilloma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40110](http://purl.obolibrary.org/obo/NCIT_C40110) (Borderline Fallopian Tube Endometrioid Tumor))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40108](http://purl.obolibrary.org/obo/NCIT_C40108) (Borderline Fallopian Tube Mucinous Tumor))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40107](http://purl.obolibrary.org/obo/NCIT_C40107) (Borderline Fallopian Tube Serous Tumor/Atypical Proliferative Serous Tumor))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40104](http://purl.obolibrary.org/obo/NCIT_C40104) (Fallopian Tube Transitional Cell Carcinoma))) 38.48%
- [NCIT:C37153](http://purl.obolibrary.org/obo/NCIT_C37153) (Malignant Stromal Cell) and (not ([NCIT:C40103](http://purl.obolibrary.org/obo/NCIT_C40103) (Fallopian Tube Mucinous Adenocarcinoma))) 38.48%


